Apixaban reduces bleeding risk versus rivaroxaban in acute venous thromboembolism
1. In a randomized controlled trial of patients with acute venous thromboembolism, apixaban was associated with a substantially lower risk...
1. In a randomized controlled trial of patients with acute venous thromboembolism, apixaban was associated with a substantially lower risk...
1. In a randomized phase 2–3 trial of patients with resectable high-risk intrahepatic cholangiocarcinoma, neoadjuvant therapy with gemcitabine–oxaliplatin, lenvatinib, and...
1. In this phase 1–2 open-label study, autologous lentiviral hematopoietic stem-cell gene therapy for cystinosis was associated with sustained engraftment...
1. In this randomized controlled trial, once-daily oral enlicitide was associated with sustained reductions in low-density lipoprotein cholesterol levels compared...
1. Among patients with previously untreated programmed death-ligand 1 positive, triple-negative breast cancer, first-line sacituzumab govitecan plus pembrolizumab significantly prolonged...
1. In this open-label phase 1–2 study, pediatric patients with mucopolysaccharidosis type II treated with tividenofusp alfa showed substantial reductions...
1. In a large randomized trial of adolescent girls, one dose of either the bivalent or nonavalent human papillomavirus (HPV)...
1. A nucleoside-modified mRNA (modRNA) influenza vaccine showed greater protection against influenza-like illness compared to a standard inactivated vaccine in...
1. In this randomized trial, aficamten monotherapy led to greater improvements in exercise capacity compared to metoprolol in patients with...
1. In this large global cohort study, individuals aged 50 without five major cardiovascular risk factors (hypertension, hyperlipidemia, abnormal body...
3-day free trial · cancel anytime
Then $4.99/month. Manage renewal in your account.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
Monthly plan selected: $4.99 /month.
3-day free trial · cancel anytime
Then $4.99/month. Manage renewal in your account.
Yearly plan selected: $49.90 /year.
2 months free
Then $49.90/year.
Already a member? Sign in